Floatz logo

NA 831

Cognitive Impairment

Biomed Industries, Inc.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

150 Active assets in the Cognitive Impairment cohort.

Asset / SponsorPhaseRating
Ginkgo Biloba Extract
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase 4BBB
Nicotine
University of Southern California
Phase 2BBB
Rivastigmine
Singapore General Hospital
Phase 4BBB
Oxybutynin
University of Alberta
Phase 4BBB
Rivastigmine
VA Office of Research and Development
Phase 4BB

View all 50 →

Same molecule, other indications

NA 831 is also rated in:

Alzheimer DementiaDormant
B
Indicative ·
57 / 100
View asset →
Cognitive DisorderDormant
B
Indicative ·
57 / 100
View asset →
vascular dementiaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →